Annals of Clinical and Translational Neurology (Sep 2024)
Application of the international criteria for optic neuritis in the Acute Optic Neuritis Network
- Philipp Klyscz,
- Susanna Asseyer,
- Ricardo Alonso,
- Charlotte Bereuter,
- Omer Bialer,
- Atira Bick,
- Sara Carta,
- John J. Chen,
- Leila Cohen,
- Yamit Cohen‐Tayar,
- Edgar Carnero Contentti,
- Russell C. Dale,
- Eoin P. Flanagan,
- Jonathan A. Gernert,
- Julian Haas,
- Joachim Havla,
- Christoph Heesen,
- Mark Hellmann,
- Netta Levin,
- Pablo Lopez,
- Itay Lotan,
- Maria Belen Luis,
- Sara Mariotto,
- Christina Mayer,
- Alvaro Jose Mejia Vergara,
- Cassandra Ocampo,
- Susana Ochoa,
- Frederike C. Oertel,
- Maja Olszewska,
- José Luis Peralta Uribe,
- Jaume Sastre‐Garriga,
- Dario Scocco,
- Sudarshini Ramanathan,
- Natthapon Rattanathamsakul,
- Fu‐Dong Shi,
- Jemal Shifa,
- Ilya Simantov,
- Sasitorn Siritho,
- Alon Tiosano,
- Nanthaya Tisavipat,
- Isabel Torres,
- Adi Vaknin Dembinsky,
- Angela Vidal‐Jordana,
- Adi Wilf‐Yarkoni,
- Ti Wu,
- Sol Zamir,
- Luis Alfonso Zarco,
- Hanna G. Zimmermann,
- Axel Petzold,
- Friedemann Paul,
- Hadas Stiebel‐Kalish
Affiliations
- Philipp Klyscz
- Experimental and Clinical Research Center A Cooperation between Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Charité ‐ Universitätsmedizin Berlin Berlin Germany
- Susanna Asseyer
- Experimental and Clinical Research Center A Cooperation between Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Charité ‐ Universitätsmedizin Berlin Berlin Germany
- Ricardo Alonso
- University Center of MS and NMOSD, Neurology Department Ramos Mejia Hospital Buenos Aires Argentina
- Charlotte Bereuter
- Experimental and Clinical Research Center A Cooperation between Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Charité ‐ Universitätsmedizin Berlin Berlin Germany
- Omer Bialer
- Department of Neuro‐Ophthalmology Rabin Medical Center Petah Tikva Israel
- Atira Bick
- Department of Neurology, Hadassah Medical Center Hebrew University Jerusalem Israel
- Sara Carta
- Neurology Unit, Department of Neurosciences, Biomedicine, and Movement Sciences University of Verona Verona Italy
- John J. Chen
- Department of Neurology Mayo Clinic Rochester Minnesota USA
- Leila Cohen
- University Center of MS and NMOSD, Neurology Department Ramos Mejia Hospital Buenos Aires Argentina
- Yamit Cohen‐Tayar
- Department of Neuro‐Ophthalmology Rabin Medical Center Petah Tikva Israel
- Edgar Carnero Contentti
- Neuroimmunology Unit, Department of Neuroscience Hospital Aleman Buenos Aires Argentina
- Russell C. Dale
- TY Nelson Department of Paediatric Neurology Children's Hospital at Westmead Sydney New South Wales Australia
- Eoin P. Flanagan
- Department of Neurology Mayo Clinic Rochester Minnesota USA
- Jonathan A. Gernert
- Institute of Clinical Neuroimmunology, LMU Hospital Ludwig‐Maximilians‐Universität Munich Munich Germany
- Julian Haas
- Experimental and Clinical Research Center A Cooperation between Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Charité ‐ Universitätsmedizin Berlin Berlin Germany
- Joachim Havla
- Institute of Clinical Neuroimmunology, LMU Hospital Ludwig‐Maximilians‐Universität Munich Munich Germany
- Christoph Heesen
- Institute of Neuroimmunology and Multiple Sclerosis University Medical Center Hamburg Eppendorf Hamburg Germany
- Mark Hellmann
- Department of Neuro‐Ophthalmology Rabin Medical Center Petah Tikva Israel
- Netta Levin
- Department of Neurology, Hadassah Medical Center Hebrew University Jerusalem Israel
- Pablo Lopez
- Neuroimmunology Unit, Department of Neuroscience Hospital Aleman Buenos Aires Argentina
- Itay Lotan
- Sackler Faculty of Medicine Tel Aviv University Tel Aviv Israel
- Maria Belen Luis
- University Center of MS and NMOSD, Neurology Department Ramos Mejia Hospital Buenos Aires Argentina
- Sara Mariotto
- Neurology Unit, Department of Neurosciences, Biomedicine, and Movement Sciences University of Verona Verona Italy
- Christina Mayer
- Institute of Neuroimmunology and Multiple Sclerosis University Medical Center Hamburg Eppendorf Hamburg Germany
- Alvaro Jose Mejia Vergara
- Ophthalmology Department University of Florida Gainesville Florida USA
- Cassandra Ocampo
- Faculty of Medicine University of Botswana Gaborone Botswana
- Susana Ochoa
- University Center of MS and NMOSD, Neurology Department Ramos Mejia Hospital Buenos Aires Argentina
- Frederike C. Oertel
- Experimental and Clinical Research Center A Cooperation between Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Charité ‐ Universitätsmedizin Berlin Berlin Germany
- Maja Olszewska
- Neuroscience Clinical Research Center (NCRC), Charité ‐ Universitätsmedizin Berlin Corporate Member of Freie Universität Berlin and Humboldt‐Universität zu Berlin Berlin Germany
- José Luis Peralta Uribe
- Pontificia Universidad Javeriana and Hospital Universitario San Ignacio Bogotá Colombia
- Jaume Sastre‐Garriga
- Neurology Department, Multiple Sclerosis Centre of Catalonia (Cemcat) Vall d’Hebron University Hospital Barcelona Spain
- Dario Scocco
- University Center of MS and NMOSD, Neurology Department Ramos Mejia Hospital Buenos Aires Argentina
- Sudarshini Ramanathan
- Faculty of Medicine and Health and Brain and Mind Centre University of Sydney Sydney New South Wales Australia
- Natthapon Rattanathamsakul
- Faculty of Medicine Siriraj Hospital Mahidol University Bangkok Bangkok Thailand
- Fu‐Dong Shi
- Department of Neurology Tianjin Medical University General Hospital Tianjin China
- Jemal Shifa
- Department of Surgery University of Botswana Gaborone Botswana
- Ilya Simantov
- Department of Neuro‐Ophthalmology Rabin Medical Center Petah Tikva Israel
- Sasitorn Siritho
- Faculty of Medicine Siriraj Hospital Mahidol University Bangkok Bangkok Thailand
- Alon Tiosano
- Department of Neuro‐Ophthalmology Rabin Medical Center Petah Tikva Israel
- Nanthaya Tisavipat
- Department of Neurology Mayo Clinic Rochester Minnesota USA
- Isabel Torres
- Pontificia Universidad Javeriana and Hospital Universitario San Ignacio Bogotá Colombia
- Adi Vaknin Dembinsky
- Department of Neurology, Hadassah Medical Center Hebrew University Jerusalem Israel
- Angela Vidal‐Jordana
- Neurology Department, Multiple Sclerosis Centre of Catalonia (Cemcat) Vall d’Hebron University Hospital Barcelona Spain
- Adi Wilf‐Yarkoni
- Neuroimmunology Service, Department of Neurology Rabin Medical Center Petah Tikva Israel
- Ti Wu
- Department of Neurology Tianjin Medical University General Hospital Tianjin China
- Sol Zamir
- Department of Neurology, Hadassah Medical Center Hebrew University Jerusalem Israel
- Luis Alfonso Zarco
- Pontificia Universidad Javeriana and Hospital Universitario San Ignacio Bogotá Colombia
- Hanna G. Zimmermann
- Experimental and Clinical Research Center A Cooperation between Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Charité ‐ Universitätsmedizin Berlin Berlin Germany
- Axel Petzold
- The National Hospital for Neurology and Neurosurgery University College London London UK
- Friedemann Paul
- Experimental and Clinical Research Center A Cooperation between Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Charité ‐ Universitätsmedizin Berlin Berlin Germany
- Hadas Stiebel‐Kalish
- Department of Neuro‐Ophthalmology Rabin Medical Center Petah Tikva Israel
- DOI
- https://doi.org/10.1002/acn3.52166
- Journal volume & issue
-
Vol. 11,
no. 9
pp. 2473 – 2484
Abstract
Abstract Objective The first international consensus criteria for optic neuritis (ICON) were published in 2022. We applied these criteria to a prospective, global observational study of acute optic neuritis (ON). Methods We included 160 patients with a first‐ever acute ON suggestive of a demyelinating CNS disease from the Acute Optic Neuritis Network (ACON). We applied the 2022 ICON to all participants and subsequently adjusted the ICON by replacing a missing relative afferent pupillary defect (RAPD) or dyschromatopsia if magnetic resonance imaging pathology of the optical nerve plus optical coherence tomography abnormalities or certain biomarkers are present. Results According to the 2022 ICON, 80 (50%) patients were classified as definite ON, 12 (7%) patients were classified as possible ON, and 68 (43%) as not ON (NON). The main reasons for classification as NON were absent RAPD (52 patients, 76%) or dyschromatopsia (49 patients, 72%). Distribution of underlying ON etiologies was as follows: 78 (49%) patients had a single isolated ON, 41 (26%) patients were diagnosed with multiple sclerosis, 25 (16%) patients with myelin oligodendrocyte glycoprotein antibody‐associated disease, and 15 (9%) with neuromyelitis optica spectrum disorder. The application of the adjusted ON criteria yielded a higher proportion of patients classified as ON (126 patients, 79%). Interpretation According to the 2022 ICON, almost half of the included patients in ACON did not fulfill the requirements for classification of definite or possible ON, particularly due to missing RAPD and dyschromatopsia. Thorough RAPD examination and formal color vision testing are critical to the application of the 2022 ICON.